Insider Selling: Invivyd (NASDAQ:IVVD) CFO Sells 20,013 Shares of Stock

Key Points

• William Duke, CFO of Invivyd, sold 20,013 shares at an average price of $0.65, decreasing his ownership by 20.22% and leaving him with 78,987 shares worth $51,341.55.
• Invivyd's recent earnings report showed a loss of ($0.12) EPS, missing estimates, with revenue of $11.79 million compared to expectations of $23.16 million.
• Institutional investors hold 70.36% of Invivyd's stock, indicating strong interest from major financial players in the company.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) CFO William Duke sold 20,013 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $0.65, for a total transaction of $13,008.45. Following the completion of the sale, the chief financial officer owned 78,987 shares in the company, valued at $51,341.55. This represents a 20.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Invivyd Trading Down 1.7%

Shares of NASDAQ:IVVD traded down $0.0101 during mid-day trading on Tuesday, reaching $0.5710. The stock had a trading volume of 1,690,635 shares, compared to its average volume of 850,421. The firm has a market cap of $68.60 million, a PE ratio of -0.62 and a beta of 0.51. The firm has a 50 day simple moving average of $0.75 and a two-hundred day simple moving average of $0.84. Invivyd, Inc. has a twelve month low of $0.3546 and a twelve month high of $2.74.

Invivyd (NASDAQ:IVVD - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.08). The firm had revenue of $11.79 million during the quarter, compared to analyst estimates of $23.16 million. Invivyd had a negative net margin of 238.33% and a negative return on equity of 177.89%. On average, equities analysts anticipate that Invivyd, Inc. will post -1.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Invivyd

A number of hedge funds and other institutional investors have recently bought and sold shares of IVVD. Catalyst Funds Management Pty Ltd acquired a new stake in Invivyd in the 2nd quarter valued at approximately $27,000. Vanguard Personalized Indexing Management LLC raised its position in Invivyd by 238.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company's stock valued at $29,000 after buying an additional 28,146 shares during the last quarter. Jane Street Group LLC raised its position in Invivyd by 290.5% in the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock valued at $52,000 after buying an additional 87,358 shares during the last quarter. Barclays PLC raised its position in Invivyd by 7.8% in the 4th quarter. Barclays PLC now owns 127,180 shares of the company's stock valued at $56,000 after buying an additional 9,207 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in Invivyd in the 1st quarter valued at approximately $65,000. Institutional investors and hedge funds own 70.36% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on IVVD shares. HC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of Invivyd in a research report on Thursday, June 26th. D. Boral Capital decreased their price objective on Invivyd from $9.00 to $3.00 and set a "buy" rating for the company in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $3.85.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.